期刊
ANNALS OF HEMATOLOGY
卷 -, 期 -, 页码 -出版社
SPRINGER
DOI: 10.1007/s00277-023-05495-w
关键词
Acute lymphoblastic leukemia; Extramedullary relapse; Inotuzumab ozogamicin; Pegaspargase; Liver failure
类别
The case of a 58-year-old female patient who experienced a relapse of extramedullary B-ALL after prior allogenic HSCT and blinatumomab therapy is presented. The patient died from complications of drug-induced acute liver failure. The combination therapy of inotuzumab ozogamicin (InO), high-dose MTX, and pegaspargase in a heavily pretreated patient with relapse after HSCT may increase the risk of liver-related toxicity. Caution is needed when assessing fitness for further liver toxic regimens. It is also important to note that InO can cause liver damage through direct hepatocellular toxicity, not just VOD.
We present the case of a 58-year-old female patient who presented with an extramedullary B-ALL relapse after prior allogenic HSCT and blinatumomab therapy. The patient died from complications of a drug-induced acute liver failure after a salvage therapy combining inotuzumab ozogamicin (InO)-based induction followed by consolidation with high dose MTX and pegaspargase based on the GMALL protocol for older ALL patients. After a diagnosis of the extramedullary relapse in the form of a retro vesical chloroma, the patient received an individualized multi-agent chemotherapy based on induction chemotherapy for older patients in combination with InO. After four administrations of InO, in combination with vincristine, dexamethasone, cytarabine, and cyclophosphamide, CT-imaging showed a reduction in volume of the chloroma and response to therapy. Consolidation with high-dose methotrexate and pegaspargase was administered. The patient developed toxic liver damage manifested by hyperbilirubinemia and progressive hepatic encephalopathy. The diagnostic criteria for VOD were met, and therapy with defibrotide was initiated. Liver biopsy revealed no histological signs of VOD but instead steatohepatitis indicative of drug-induced toxicity. The patient ultimately died of hemorrhagic shock through postinterventional hemorrhage after liver biopsy. In conclusion, although InO shows promising results in the therapy of r/r ALL with and without additional chemotherapy, the combination with MTX and pegaspargase in an intensively pretreated patient with relapse after HCST may impart an increased risk for liver-related toxicity. Special caution is required when assessing fitness for further liver toxic regimens. A key takeaway is also the reminder that InO can cause liver damage not only in the form of VOD but also through direct hepatocellular toxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据